ECSP12011610A - Inhibidores de la replicación de los virus de la gripe - Google Patents

Inhibidores de la replicación de los virus de la gripe

Info

Publication number
ECSP12011610A
ECSP12011610A EC2012011610A ECSP12011610A ECSP12011610A EC SP12011610 A ECSP12011610 A EC SP12011610A EC 2012011610 A EC2012011610 A EC 2012011610A EC SP12011610 A ECSP12011610 A EC SP12011610A EC SP12011610 A ECSP12011610 A EC SP12011610A
Authority
EC
Ecuador
Prior art keywords
pharmaceutically acceptable
structural formula
patient
replication
acceptable salt
Prior art date
Application number
EC2012011610A
Other languages
English (en)
Inventor
Marion W Wannamaker
John Court
Joseph Henry Kennedy
Emanuele Perola
Paul Charifson
Francois Maltais
Michael P Clark
Upul K Bandarage
Randy S Bethiel
Hongbo Deng
Loana Drutu
John P Duffy
Luc Farmer
Huai Gao
Wenxin Gu
Dylan H Jacobs
Mark Ledeboer
Brian Ledford
Tiansheng Wang
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42537408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011610(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ECSP12011610A publication Critical patent/ECSP12011610A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para inhibir la replicación de los virus de influenza en una muestra biológica o paciente o reducir la cantidad de virus de influenza en una muestra biológica o paciente y tratar influenza en un paciente que comprenden administrar a dicha muestra biológica o paciente una cantidad efectiva de un compuesto representado por la Fórmula Estructural (I):(IA),o una sal farmacéuticamente aceptable del mismo, en donde los valores de Fórmula Estructural (IA) son como se describen en la presente. Un compuesto está representado por la Fórmula Estructural (IA) o una sal farmacéuticamente aceptable del mismo, en donde los valores de Fórmula Estructural (IA) son como se describen en la presente. Una composición farmacéutica comprende una cantidad efectiva de dicho compuesto o sal farmacéuticamente aceptable del mismo y un portador, adyuvante o vehículo farmacéuticamente aceptable.
EC2012011610A 2009-06-17 2012-01-17 Inhibidores de la replicación de los virus de la gripe ECSP12011610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18771309P 2009-06-17 2009-06-17
US28778109P 2009-12-18 2009-12-18

Publications (1)

Publication Number Publication Date
ECSP12011610A true ECSP12011610A (es) 2012-02-29

Family

ID=42537408

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2012011610A ECSP12011610A (es) 2009-06-17 2012-01-17 Inhibidores de la replicación de los virus de la gripe

Country Status (37)

Country Link
US (7) US20120171245A1 (es)
EP (3) EP3141252B8 (es)
JP (6) JP5721706B2 (es)
KR (3) KR101702609B1 (es)
CN (5) CN104151312B (es)
AP (1) AP3631A (es)
AR (1) AR077130A1 (es)
AU (1) AU2010262905B2 (es)
BR (1) BRPI1011993A2 (es)
CA (1) CA2764177C (es)
CL (1) CL2011003192A1 (es)
CO (1) CO6491048A2 (es)
CY (2) CY1118246T1 (es)
DK (2) DK2442809T3 (es)
EA (3) EA030188B1 (es)
EC (1) ECSP12011610A (es)
ES (2) ES2692396T3 (es)
GE (5) GEAP202213376A (es)
HR (2) HRP20161577T1 (es)
HU (1) HUE031048T2 (es)
IL (2) IL216980B (es)
LT (2) LT3141252T (es)
ME (1) ME02558B (es)
MX (3) MX2011013475A (es)
NZ (2) NZ597059A (es)
PE (2) PE20120508A1 (es)
PH (1) PH12015501678B1 (es)
PL (2) PL3141252T3 (es)
PT (2) PT2442809T (es)
RS (2) RS55341B1 (es)
SG (3) SG176722A1 (es)
SI (2) SI2442809T1 (es)
TR (1) TR201815272T4 (es)
TW (4) TWI639596B (es)
UY (1) UY32717A (es)
WO (1) WO2010148197A1 (es)
ZA (2) ZA201109127B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ564065A (en) * 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
GEAP202213376A (en) 2009-06-17 2022-02-25 Vertex Pharmaceuticals Incorporated Us Inhibitors of influenza viruses replication
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
JP2013545818A (ja) * 2010-12-16 2013-12-26 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製阻害物質
EP2651941A1 (en) * 2010-12-16 2013-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US9181279B2 (en) 2011-07-04 2015-11-10 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor antagonists
NZ619699A (en) 2011-07-05 2016-03-31 Vertex Pharma Processes and intermediates for producing azaindoles
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US10323012B2 (en) * 2012-06-05 2019-06-18 Hong Kong Baptist University Miliusanes as antiviral agents
EP2858984A1 (en) * 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
EA035349B1 (ru) 2012-11-21 2020-05-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
WO2015030847A1 (en) 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
HUE052178T2 (hu) * 2013-11-13 2021-04-28 Vertex Pharma Eljárások influenzavírus-replikáció inhibitorainak elõállítására
LT3068776T (lt) * 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
AU2014348762A1 (en) * 2013-11-13 2016-05-26 Vertex Pharmaceuticals Incorporated Formulations of azaindole compounds
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
LT3126352T (lt) 2014-04-04 2019-01-10 Syros Pharmaceuticals, Inc. Nuo ciklino priklausomos kinazės 7 (cdk7) inhibitoriai
MA40547A (fr) 2014-08-08 2017-06-14 Janssen Sciences Ireland Uc Indoles pouvant être utilisés dans l'infection par le virus influenza
SI3191489T1 (sl) * 2014-09-08 2021-02-26 Janssen Sciences Ireland Unlimited Company Pirolopirimidini za uporabo pri okužbi z virusom gripe
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
JP6660393B2 (ja) * 2015-01-16 2020-03-11 バイエル・クロップサイエンス・アクチェンゲゼルシャフト ４−シアノピペリジン塩酸塩を調製する方法
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2016191079A1 (en) * 2015-05-26 2016-12-01 Boropharm, Inc. Improved process for preparing boryl 7-azaindole compounds
CA3005514A1 (en) 2015-11-27 2017-06-01 Janssen Sciences Ireland Uc Heterocyclic indoles for use in influenza virus infection
JP6952695B2 (ja) * 2015-12-09 2021-10-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． インフルエンザウイルス複製の阻害剤、その適用方法および使用
KR20180099839A (ko) * 2016-01-07 2018-09-05 얀센 사이언시즈 아일랜드 유씨 인플루엔자 바이러스 감염에서 사용하기 위한 작용화된 펜탄산
DK3405466T3 (da) * 2016-01-20 2021-02-01 Janssen Sciences Ireland Unlimited Co Arylsubstituerede pyrimidiner til anvendelse ved influenzavirusinfektion
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017198122A1 (zh) * 2016-05-19 2017-11-23 四川大学 抗流感小分子化合物及其制备方法和用途
WO2018033082A1 (en) * 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2018041091A1 (en) 2016-08-30 2018-03-08 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
KR102312088B1 (ko) * 2016-09-05 2021-10-14 광둥 레이노벤트 바이오테크 컴퍼니 리미티드 항인플루엔자 바이러스 피리미딘 유도체
US11020396B2 (en) * 2016-11-08 2021-06-01 Cancer Research Technology Limited Pyrimidinone derivatives as Cdc7 inhibitors
EP3555095B1 (en) * 2016-12-15 2023-04-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CA3047404A1 (en) * 2016-12-23 2018-06-28 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
WO2018127096A1 (en) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
US10927118B2 (en) 2017-03-02 2021-02-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
JP2020516634A (ja) 2017-04-12 2020-06-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルス感染の処置方法および併用療法
SG11201909478UA (en) * 2017-04-24 2019-11-28 Cocrystal Pharma Inc Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
CN108727369B (zh) * 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
MA49858A (fr) 2017-08-09 2021-04-28 Denali Therapeutics Inc Composés, compositions et procédés
DK3676297T3 (da) 2017-09-01 2023-08-14 Denali Therapeutics Inc Forbindelser, sammensætninger og fremgangsmåder
CN109745309B (zh) * 2017-11-03 2022-01-28 香港浸会大学 作为抗病毒剂的密瘤杀
CN110117285B (zh) * 2018-02-07 2023-02-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CA3092315C (en) 2018-03-05 2023-08-29 Jian Xiong Crystal form and salt form of pyridopyrazole compound and preparation method therefor
JP2021520363A (ja) 2018-04-06 2021-08-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 結晶形態のピモジビル塩酸塩半水和物を調製するための等温反応性結晶化方法
CN110590768B (zh) * 2018-06-13 2021-02-26 银杏树药业(苏州)有限公司 杂环化合物、其组合物及其作为抗流感病毒药物的应用
EP3829719B1 (en) * 2018-07-27 2025-04-02 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
AU2019340402B2 (en) 2018-08-17 2025-04-03 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
SG11202108552QA (en) 2019-02-13 2021-09-29 Denali Therapeutics Inc Compounds, compositions and methods
MA54959A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
US20220177456A1 (en) * 2019-03-06 2022-06-09 Denali Therapeutics Inc. Compounds, compositions and methods
WO2020212399A1 (en) 2019-04-15 2020-10-22 Janssen Pharmaceutica Nv Method for preparing an alkyl trans-3-aminobicyclo[2.2.2]octane-2-carboxylic acid ester compound
WO2020256820A1 (en) 2019-06-20 2020-12-24 Janssen Pharmaceuticals, Inc. Formulations of azaindole compounds
EP3992192B1 (en) 2019-07-22 2026-02-18 Guangdong Raynovent Biotech Co., Ltd. Dominant salt forms of pyrimidine derivatives, and crystal forms thereof
EP4023647B1 (en) * 2019-08-30 2025-04-09 TSD Life Sciences Co., Ltd. Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
CN114502150B (zh) * 2019-09-10 2023-03-24 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
RU2726119C1 (ru) * 2019-11-22 2020-07-09 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые производные полиолов, их применение, фармацевтическая композиция на их основе
CN117362318A (zh) 2020-07-10 2024-01-09 西藏海思科制药有限公司 Pb2抑制剂及其制备方法和用途
CN112979647B (zh) * 2021-03-12 2022-05-20 浙江大学 含氮杂氨基酸的氮杂吲哚衍生物及制备和应用

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349552A (en) 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
NZ221717A (en) 1986-09-10 1990-08-28 Sandoz Ltd Azaindole and indolizine derivatives and pharmaceutical compositions
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
WO1995033748A1 (en) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
US6187713B1 (en) 1996-10-31 2001-02-13 Corning Incorporated Method of making activated carbon bodies having improved adsorption properties
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
EP1147083B1 (en) 1999-01-07 2004-06-16 Wyeth Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
WO2000040581A1 (en) 1999-01-07 2000-07-13 American Home Products Corporation 3,4-dihydro-2h-benzo[1,4]oxazine derivatives
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
AR028475A1 (es) 1999-04-22 2003-05-14 Wyeth Corp Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
US20030153560A1 (en) 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
JP2003503456A (ja) 1999-07-02 2003-01-28 スチュアート エイ． リプトン 神経傷害またはアポトーシスを軽減する方法
GB9919843D0 (en) 1999-08-20 1999-10-27 Smithkline Beecham Plc Novel compounds
DE19948417A1 (de) 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
EP1246823A1 (en) 1999-12-28 2002-10-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
MXPA02007957A (es) 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
US7041277B2 (en) 2000-03-10 2006-05-09 Cadbury Adams Usa Llc Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
NZ524192A (en) 2000-08-14 2005-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
ES2309088T3 (es) 2000-09-06 2008-12-16 Ortho-Mcneil Pharmaceutical, Inc. Uso de pirazoles sustituidos para el tratamiento de alergias.
HK1053129A1 (zh) 2000-09-06 2003-10-10 Ortho-Mcneil Pharmaceutical, Inc. 治疗变态反应的方法
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
JP2004509897A (ja) 2000-09-22 2004-04-02 イーライ・リリー・アンド・カンパニー シクロヘキシルアミン誘導体の立体選択的製造方法
JP4307073B2 (ja) 2000-12-22 2009-08-05 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロサイクルインダゾールおよびアザインダゾール化合物
CA2439263C (en) 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
PT1392697E (pt) 2001-03-14 2005-01-31 Wyeth Corp Antidepressivos derivados aza-heterociclilmetilo de 2,3- di-hidro-1,4-dioxino[2,3-f]quinolina
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
EP1381600A1 (en) 2001-04-24 2004-01-21 Wyeth, A Corporation of the State of Delaware Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
US6656950B2 (en) 2001-04-25 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
US6593350B2 (en) 2001-04-26 2003-07-15 Wyeth Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
JP2004532236A (ja) 2001-04-26 2004-10-21 ワイス 抗うつ作用を持つ、オキサヘテロ環結合［１、４］−ベンゾジオキサンのアザヘテロシクリルメチル誘導体
EP1381612A1 (en) 2001-04-26 2004-01-21 Wyeth Antidepressant aza-heterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline
JP2004527563A (ja) 2001-04-26 2004-09-09 ワイス 抗うつ作用を有する、２，３−ジヒドロ−１，４−ジオキシノ［２，３−ｆ］キノキサリンのアザへテロシクリルメチル誘導体
BR0209408A (pt) 2001-04-26 2004-07-06 Wyeth Corp Antidepressivos de azaheterociclilmetila derivados de 7,8-dihidro-3h-6,9-dioxa-1,3-diaza-ciclopenta[a]naftal eno, método de tratamento usando tais compostos e processo para prepará-los
US6555560B2 (en) 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
CN1256337C (zh) 2001-04-30 2006-05-17 惠氏公司 抗抑郁的7,8－二氢－1,6,9－三氧杂－3－氮杂－环戊二烯并[a]萘的氮杂环基甲基衍生物
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
MXPA03010524A (es) 2001-05-17 2005-03-07 Wyeth Corp Proceso para la sintesis de derivados de la 2,3-dihidro-1,4-dioxino-[2,3-f]-quinolina.
US6825190B2 (en) 2001-06-15 2004-11-30 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003010169A1 (en) 2001-07-25 2003-02-06 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7, 8-dihydro-6h-5-oxa-1-aza-phenanthrene
KR100894167B1 (ko) 2001-08-14 2009-04-22 토야마 케미칼 컴퍼니 리미티드 신규의 바이러스 증식저해 ·살바이러스방법 및 신규의피라진뉴클레오티드 ·피라진뉴클레오시드 유사체
US20040236110A1 (en) 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
WO2003031439A1 (en) 2001-10-05 2003-04-17 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
DE60302150D1 (en) 2002-04-26 2005-12-08 Pfizer Prod Inc N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
DE60308387T2 (de) 2002-08-02 2007-09-20 Vertex Pharmaceuticals Inc., Cambridge Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
AU2002368154A1 (en) 2002-08-08 2004-02-25 Ribapharm Inc. Improved synthesis for hydroxyalkylated heterocyclic bases
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
UA80743C2 (en) 2003-02-26 2007-10-25 Boehringer Ingelheim Pharma Dihydropteridinones, method for the production and use thereof in the form of drugs
EP2295433A3 (en) 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
ES2317031T3 (es) 2003-07-16 2009-04-16 Janssen Pharmaceutica Nv Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3.
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
WO2005033072A2 (en) 2003-09-30 2005-04-14 Scios Inc. Heterocyclic amides and sulfonamides
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
NZ584499A (en) 2004-03-30 2011-08-26 Vertex Pharma Azaindoles Useful as Inhibitors of Jak and Other Protein Kinases
TW200604168A (en) 2004-04-02 2006-02-01 Vertex Pharma Azaindoles useful as inhibitors of rock and other protein kinases
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
KR100476851B1 (ko) 2004-05-18 2005-03-17 (주)성신엔지니어링 중력식 섬유여과기
CA2570817A1 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20060122213A1 (en) 2004-06-30 2006-06-08 Francoise Pierard Azaindoles useful as inhibitors of protein kinases
US7361763B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2582235A1 (en) 2004-10-04 2006-04-20 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
EP1812440B1 (en) 2004-11-04 2010-09-22 Vertex Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
EP1814883A1 (en) 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
EP2522365B1 (en) 2004-11-24 2016-10-26 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20090233955A1 (en) 2004-12-08 2009-09-17 Frazee James S 1H-Pyrrolo[2,3-B]Pyridnes
EP1831168B1 (en) 2004-12-16 2014-07-02 Vertex Pharmaceuticals Inc. Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases.
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
RU2434871C2 (ru) 2005-02-03 2011-11-27 Вертекс Фармасьютикалз Инкорпорейтед Пирролопиримидины, применимые в качестве ингибиторов протеинкиназы
AU2006247322A1 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
NZ564065A (en) 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
PL2395004T3 (pl) 2005-06-22 2016-08-31 Plexxikon Inc Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
EP2532667A1 (en) 2005-09-30 2012-12-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
US20130096302A1 (en) 2005-11-22 2013-04-18 Hayley Binch Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
AR060316A1 (es) 2006-01-17 2008-06-11 Vertex Pharma Azaindoles de utilidad como inhibidores de janus quinasas
CA2652648C (en) 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
CA2641254A1 (en) 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
CN101460499A (zh) 2006-04-05 2009-06-17 沃泰克斯药物股份有限公司 可用作janus激酶抑制剂的去氮杂嘌呤
US8252792B2 (en) * 2006-04-26 2012-08-28 F. Hoffman-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US20090017444A1 (en) 2006-06-09 2009-01-15 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
BRPI0714908B8 (pt) 2006-08-08 2021-05-25 Chugai Pharmaceutical Co Ltd derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
WO2008023159A1 (en) * 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CA2672612A1 (en) 2006-12-14 2008-06-26 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
US8247421B2 (en) 2006-12-21 2012-08-21 Vertex Pharmaceuticals Incorporated 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
EP2137183B1 (en) 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
EP2134709A1 (en) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Aminopyridines useful as inhibitors of protein kinases
WO2008112642A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CN102746175B (zh) 2007-03-22 2014-01-15 武田药品工业株式会社 可用作plk1抑制剂的取代的嘧啶并二氮杂*
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
JP5580731B2 (ja) 2007-04-05 2014-08-27 アンドレイ・アレクサンドロビッチ・イワシェンコ 置換された２，３，４，５−テトラヒドロ−１ｈ−ピリド［４，３−ｂ］インドール、その製造のための方法及び使用
US8461149B2 (en) 2007-08-15 2013-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
EP2610256B1 (en) 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
SG185289A1 (en) 2007-10-09 2012-11-29 European Molecular Biology Lab Embl Soluble fragments of influenza virus pb2 protein capable of binding rna-cap
CA2704266A1 (en) 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
SI2207775T1 (sl) 2007-11-05 2012-05-31 Novartis Ag benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza
MX2010008198A (es) 2008-02-25 2010-08-23 Hoffmann La Roche Inhibidores de cinasa de pirrolopirazina.
EP2262498A2 (en) 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
US20110033473A1 (en) 2008-04-09 2011-02-10 Yoram Reiter Anti influenza antibodies and uses thereof
MX2011000021A (es) 2008-06-23 2011-02-24 Vertex Pharma Inhibidores de proteina cinasas.
MX2011000026A (es) 2008-06-23 2011-02-24 Vertex Pharma Inhibidores de proteina cinasas.
AU2009274017A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
EP2318407B1 (en) 2008-07-23 2013-01-02 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
JP5631310B2 (ja) 2008-07-23 2014-11-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 三環式ピラゾロピリジンキナーゼ阻害剤
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010129668A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
US20120093738A1 (en) 2009-06-11 2012-04-19 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
GEAP202213376A (en) * 2009-06-17 2022-02-25 Vertex Pharmaceuticals Incorporated Us Inhibitors of influenza viruses replication
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
CA2767089A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CN102933206A (zh) 2010-04-07 2013-02-13 弗特克斯药品有限公司 3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式
PH12012502046A1 (en) 2010-04-14 2017-07-26 Array Biopharma Inc 5,7-substituted~imidazo[1,2-c]pyrimidines as inhibitors of jak kinases
WO2011137022A1 (en) 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors
JP2013545818A (ja) 2010-12-16 2013-12-26 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製阻害物質
EP2651941A1 (en) 2010-12-16 2013-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
NZ619699A (en) 2011-07-05 2016-03-31 Vertex Pharma Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
MX2014005565A (es) 2011-11-07 2014-05-30 Vertex Pharma Metodos para tratar enfermedades inflamatorias y composiciones farmaceuticas utiles para los mismos.
EP2858984A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
WO2014201332A1 (en) 2013-06-14 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical combinations useful for treating rheumatoid arthritis
CA2921198A1 (en) 2013-08-22 2015-02-26 Vertex Pharmaceuticals Incorporated Isotopically enriched azaindoles
AU2014318832B2 (en) 2013-09-12 2018-11-29 Janssen Biopharma, Inc. Aza-pyridone compounds and uses thereof
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
HUE052178T2 (hu) 2013-11-13 2021-04-28 Vertex Pharma Eljárások influenzavírus-replikáció inhibitorainak elõállítására
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
AU2014348762A1 (en) 2013-11-13 2016-05-26 Vertex Pharmaceuticals Incorporated Formulations of azaindole compounds
MA40547A (fr) 2014-08-08 2017-06-14 Janssen Sciences Ireland Uc Indoles pouvant être utilisés dans l'infection par le virus influenza
SI3191489T1 (sl) 2014-09-08 2021-02-26 Janssen Sciences Ireland Unlimited Company Pirolopirimidini za uporabo pri okužbi z virusom gripe
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
CA3005514A1 (en) 2015-11-27 2017-06-01 Janssen Sciences Ireland Uc Heterocyclic indoles for use in influenza virus infection
KR20180099839A (ko) 2016-01-07 2018-09-05 얀센 사이언시즈 아일랜드 유씨 인플루엔자 바이러스 감염에서 사용하기 위한 작용화된 펜탄산
DK3405466T3 (da) 2016-01-20 2021-02-01 Janssen Sciences Ireland Unlimited Co Arylsubstituerede pyrimidiner til anvendelse ved influenzavirusinfektion
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
JP2020516634A (ja) 2017-04-12 2020-06-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルス感染の処置方法および併用療法

Also Published As

Publication number Publication date
SG176722A1 (en) 2012-01-30
PL2442809T3 (pl) 2017-02-28
AU2010262905B2 (en) 2015-04-16
IL216980A0 (en) 2012-02-29
EP3141252B8 (en) 2019-03-13
HK1169326A1 (en) 2013-01-25
KR101903354B1 (ko) 2018-10-04
JP2015034177A (ja) 2015-02-19
US20120171245A1 (en) 2012-07-05
HK1204322A1 (en) 2015-11-13
AP3631A (en) 2016-03-08
PT2442809T (pt) 2016-12-06
EP3141252B1 (en) 2018-07-25
EP3427738A1 (en) 2019-01-16
GEP20227397B (en) 2022-07-25
RS55341B1 (sr) 2017-03-31
EA201500266A1 (ru) 2015-10-30
EP3427738B1 (en) 2021-12-01
LT2442809T (lt) 2016-12-12
HUE031048T2 (en) 2017-06-28
TWI483941B (zh) 2015-05-11
JP2015038146A (ja) 2015-02-26
NZ597059A (en) 2014-01-31
KR101702609B1 (ko) 2017-02-03
EA201500871A1 (ru) 2016-11-30
RS57869B1 (sr) 2018-12-31
HRP20181715T1 (hr) 2019-04-05
AU2010262905A1 (en) 2012-01-12
JP2012530713A (ja) 2012-12-06
CN104922128B (zh) 2019-12-20
PE20160127A1 (es) 2016-02-24
TW201728584A (zh) 2017-08-16
HK1215530A1 (zh) 2016-09-02
US10039762B2 (en) 2018-08-07
PL3141252T3 (pl) 2019-01-31
EA201500871A8 (ru) 2019-02-28
EP2442809A1 (en) 2012-04-25
JP6030619B2 (ja) 2016-11-24
IL216980B (en) 2018-11-29
EA025276B1 (ru) 2016-12-30
TW201520211A (zh) 2015-06-01
CL2011003192A1 (es) 2013-01-04
EA037529B1 (ru) 2021-04-08
PT3141252T (pt) 2018-11-14
SG10201405826RA (en) 2014-12-30
TWI574963B (zh) 2017-03-21
KR20120097471A (ko) 2012-09-04
GEAP202213376A (en) 2022-02-25
US20140142119A1 (en) 2014-05-22
NZ619259A (en) 2015-07-31
ES2604667T3 (es) 2017-03-08
US9808459B2 (en) 2017-11-07
US20140296201A1 (en) 2014-10-02
US10874673B2 (en) 2020-12-29
ZA201500820B (en) 2016-05-25
MX2011013475A (es) 2012-03-14
CN104940202A (zh) 2015-09-30
SI3141252T1 (sl) 2018-12-31
US20190151314A1 (en) 2019-05-23
EA030188B1 (ru) 2018-07-31
SI2442809T1 (sl) 2017-01-31
EP3141252A1 (en) 2017-03-15
CA2764177A1 (en) 2010-12-23
CN104151312A (zh) 2014-11-19
CN104940202B (zh) 2018-10-16
JP6348939B2 (ja) 2018-06-27
BRPI1011993A2 (pt) 2021-07-06
EP2442809B1 (en) 2016-08-31
JP6620135B2 (ja) 2019-12-11
UY32717A (es) 2011-01-31
MX348066B (es) 2017-05-26
GEP20207129B (en) 2020-07-10
PE20120508A1 (es) 2012-05-09
US9518056B2 (en) 2016-12-13
LT3141252T (lt) 2018-11-12
WO2010148197A1 (en) 2010-12-23
AR077130A1 (es) 2011-08-03
CN110540538A (zh) 2019-12-06
JP2016204390A (ja) 2016-12-08
AP2012006067A0 (en) 2012-02-29
GEAP202013375A (en) 2020-02-10
TWI639596B (zh) 2018-11-01
ME02558B (me) 2017-02-20
JP5721706B2 (ja) 2015-05-20
KR20180108856A (ko) 2018-10-04
SG10201405827PA (en) 2014-11-27
HK1215675A1 (zh) 2016-09-09
KR102050712B1 (ko) 2019-12-02
PH12015501678A1 (en) 2020-06-22
CO6491048A2 (es) 2012-07-31
IL262734B (en) 2020-11-30
US20170100400A1 (en) 2017-04-13
MX375432B (es) 2025-03-06
CY1118246T1 (el) 2017-06-28
DK2442809T3 (en) 2016-12-19
GEP20156325B (en) 2015-07-10
JP2018002747A (ja) 2018-01-11
CN102458408B (zh) 2015-06-03
DK3141252T3 (en) 2018-11-19
US20160152614A1 (en) 2016-06-02
CA2764177C (en) 2018-06-05
CN102458408A (zh) 2012-05-16
US8829007B2 (en) 2014-09-09
EA201270032A1 (ru) 2012-07-30
CN104151312B (zh) 2016-06-15
CN104922128A (zh) 2015-09-23
TW201925196A (zh) 2019-07-01
IL262734A (en) 2018-12-31
ES2692396T3 (es) 2018-12-03
KR20170015551A (ko) 2017-02-08
HRP20161577T1 (hr) 2017-01-27
JP2020011990A (ja) 2020-01-23
CY1120778T1 (el) 2019-12-11
TWI666209B (zh) 2019-07-21
PH12015501678B1 (en) 2022-07-06
TW201103935A (en) 2011-02-01
US20180078553A1 (en) 2018-03-22
TR201815272T4 (tr) 2018-11-21
US9345708B2 (en) 2016-05-24
ZA201109127B (en) 2015-07-29

Similar Documents

Publication Publication Date Title
ECSP12011610A (es) Inhibidores de la replicación de los virus de la gripe
ECSP14013189A (es) Inhibidores de la replicación de los virus de la gripe
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.
WO2012083122A8 (en) Inhibitors of influenza viruses replication
UY32062A (es) Inhibidores de beta-secretasa
MX2012015097A (es) Derivados de acido naft-2-ilacetico para tratar sida.
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
UY33897A (es) Inhibidores del virus de la hepatitis c
MX342212B (es) Inhibidores de neprilisina.
UY34066A (es) Inhibidores del virus de la hepatitis c
UY33473A (es) Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
BR112014010401A8 (pt) Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
MX2019012759A (es) Derivados de pirrolopirimidina utiles como inhibidores de la replicacion de los virus de la gripe.
EA201691083A1 (ru) Ингибиторы репликации вирусов гриппа
AR113753A2 (es) Inhibidores de la replicación del virus de la gripe, compuesto, método de preparación
UA111703C2 (uk) Інгібітори реплікації вірусів грипу
CO6290680A2 (es) Inhibidores de virus de la hepatitis c